CX3CL1 and Miyoshi myopathy: Our evidence showing the involvement of CX3CL1 in MM-induced angiogenesis, together with the pro-inflammatory bone microenvironment that characterized MM patients [51], gives the rationale to test this possible therapeutic approach by blocking the CX3CL1/CX3R1 axis in MM also.